UCB (OTCMKTS:UCBJF) Stock Price Down 4.8% – What’s Next?

UCB SA (OTCMKTS:UCBJF) shares dropped 4.8% on Monday . The company traded as low as $233.86 and last traded at $238.40. Approximately 412 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 689 shares. The stock had previously closed at $250.52.

Wall Street Analysts Forecast Growth

UCBJF has been the subject of a number of analyst reports. Jefferies Financial Group upgraded UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler restated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, UCB presently has an average rating of “Moderate Buy”.

UCB Price Performance

The company’s 50 day moving average price is $263.68 and its 200-day moving average price is $285.27. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.